ag 1879 has been researched along with Leukemia, Myeloid in 4 studies
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jensen, HA | 1 |
| Styskal, LE | 1 |
| Tasseff, R | 1 |
| Bunaciu, RP | 1 |
| Congleton, J | 3 |
| Varner, JD | 1 |
| Yen, A | 3 |
| Shen, M | 1 |
| MacDonald, R | 2 |
| Malavasi, F | 1 |
| Okamoto, M | 1 |
| Hayakawa, F | 1 |
| Miyata, Y | 1 |
| Watamoto, K | 1 |
| Emi, N | 1 |
| Abe, A | 1 |
| Kiyoi, H | 1 |
| Towatari, M | 1 |
| Naoe, T | 1 |
4 other studies available for ag 1879 and Leukemia, Myeloid
| Article | Year |
|---|---|
The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; CD11b Antigen; Cell Differentiation; Drug Resistance, | 2013 |
Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity.
Topics: Adaptor Proteins, Signal Transducing; ADP-ribosyl Cyclase 1; Antineoplastic Agents; Cell Differentia | 2014 |
Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Differentiation; Dasatinib; Extracellular | 2012 |
Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Topics: Acute Disease; Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line; Drug Design; Drug Scr | 2007 |